CLINICAL_TRIALS
trial_result
· 2024-06-11
Clinical Trial Update: Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis [Phase 2]
Summary
Phase 2 long-term safety update of ARQ-154 Foam in subjects with seborrheic dermatitis, reporting extended-use safety data.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Seborrheic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-06-11